InVivo Biosystems specializes in providing CRISPR genome edited animal models and in vivo analytical services, primarily serving pharmaceutical, nutraceutical, biotechnology companies, and research institutions. Operating in the early-stage disease studies and drug discovery market, the company offers customized genome-edited C. elegans and zebrafish models to facilitate in vivo insights into human biology. InVivo Biosystems' business model revolves around offering turnkey services that help clients visualize and measure animal behavior, collect phenotypic data, and make informed decisions on their research hypotheses. The company generates revenue through the sale of its genome editing services, analytical tools, and consulting expertise. Additionally, InVivo Biosystems provides data analysis and expert consultation to help clients understand their research results and explore alternative hypotheses.

Keywords: CRISPR, genome editing, animal models, in vivo analysis, disease studies, drug discovery, C. elegans, zebrafish, phenotypic data, biotechnology.